Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 preclinical gene therapy for polycystic kidney disease (600K US patients) using AI-driven target identification; $1.1M raised with NIH SBIR grant, raising $4M seed competing with CRISPR Therapeutics for curative kidney genetic medicine.
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
German craftsman AI voice agent answering calls and scheduling 24/7 for 1M+ Handwerk businesses; YC-backed targeting phone automation for HVAC, plumbing, and electrical trades in Germany.
Hey Telo is a Berlin-based AI voice agent company building phone-answering and administrative automation specifically for Germany's 1 million+ independent craftsman businesses (Handwerksbetriebe) — HVAC technicians, plumbers, electricians, carpenters, and other skilled trades — who lose significant revenue daily to unanswered calls and administrative burden. A Y Combinator-backed startup, Hey Telo provides voice AI agents that answer calls professionally 24/7, schedule appointments, and provide quotes while the craftsman is on-site working.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.